Another Case of a Pharma Monopoly

In the past, we’ve seen cases where pharmaceutical companies have virtual monopolies on drugs and courses of treatment e.g. Duripram.  Here is another case, where this time its is the maker of Epi-Pen which has a monopoly on a highly inelastic good.

The question has come up time and again, is it ethical to take advantage of the market in way which maximizes profits?  From our coursework, we would expect this firm to raise prices along with total revenue, since the good is almost perfectly inelastic.  Where do you stand on this?